Author + information
Over a period of 26 years we treated 37 consecutive patients with a CMV-PCR positive, histologically validated myocarditis with either CMV hyperimmunoglobulin (CMVhIg)in addition to heart failure therapy or with heart failure therapy alone.
19 pts received 2ml/kg i.v. for 3 and 1ml/kg for 2 additional 2 days alternately, 18 patients served as controls. Results Cellular infiltrates were eliminated in 15 out 18 pts (p<0,01) and CMV-DNA 14 out of 19 pts (p<0.01) in the CMVhIg treatment group.
Cellular infiltrates were eliminated in 15 out 18 pts (p<0,01) and CMV-DNA 14 out of 19 pts (p55%) in 16/18) of the CMVhIg treated patients. In the control group with heart failure treatment alone (n=18) spontaneous improvement by one NYHA class or more was observed in 3 out 18 pts and by EF in 7 out of 18 pts. Resolution of the infiltrate occurred and a negative PCR for CMV-DNA was seen in 3/17 at control biopsy.
CMV-hIg treatment eliminates CMV-DNA and inflammatory cells effectively from the myocardium. CVB, HIV and hepatitis infection could be excluded after therapy with CMV-hlg.
|Elimination of inflammation and CMV genome|
|ivIG therapy + HF therapy (19) in %||heart failure(HF) therapy only(18) in %||p<(chi²)|
|Elimination of infiltrates||79||22||0,01|
|eradication of CMV-DNA||74||17||0,01|
|elimination of CMV-DNA & of infiltrate||74||17||0,01|
|improved NYHA class||84||17||0,01|
|improved EF by >5% or normalized||84||39||0,05|
Poster Area, South Hall A1
Saturday, April 02, 2016, 10:00 a.m.-10:45 a.m.
Session Title: Heart Failure and Cardiomyopathies: Medical Therapy
Abstract Category: 27. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1103-077
- 2016 American College of Cardiology Foundation